Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective
Understanding immune cell diversity in checkpoint inhibitor therapy reveals why some patients respond better, pointing toward smarter ways to enhance cancer immunotherapy.
This single-cell perspective review comprehensively synthesizes macrophage subpopulation heterogeneity in the context of checkpoint inhibitor therapy, identifying macrophage diversity as a key determinant of both anti-tumor efficacy and immune toxicity. The review provides a mechanistic framework for macrophage-targeting approaches to improve immunotherapy outcomes.
What the study was
- Study design
- Narrative review (scRNA-seq data synthesis)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cellular & Molecular Biology Letters
Why it surfaced
scRNA-seq-based macrophage heterogeneity review with actionable mechanistic insight for immunotherapy optimization. Review design limits score; no primary clinical data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.